Is HoFH hiding in your practice?
Homozygous familial hypercholesterolemia (HoFH) is an ultra rare, inherited genetic disorder of lipid metabolism1,2
HoFH is characterized by:1-4
- Markedly elevated plasma levels of LDL-C (untreated LDL-C >10 mmol/L)3
- Premature atherosclerotic cardiovascular disease and cardiovascular morbidity and mortality
-
Cholesterol buildup:
- around the joints and on the tendons (xanthomas)
- in the eyes (corneal arcus) and around the eyelids (xanthelasmas)
The current estimated prevalence of HoFH is 1 in 300,000.4
Prevalence is higher in these groups:
- 1 in 275,000 French Canadians5
- 1 in 30,000 Afrikaners in South Africa6
- 1 in 10,000 Christian Lebanese7
HoFH is genetic and inherited
HoFH occurs when two copies of the alleles bearing the familial hypercholesterolemia (FH)-causing genes are inherited, one from each parent.1
HoFH differs from HeFH
Homozygous FH (HoFH)3 | Heterozygous FH (HeFH)3 |
---|---|
Mutated genes inherited from both parents | Mutated gene inherited from one parent |
Occurs in 1 in 300,000 persons | Occurs in 1 in 250 persons |
LDL-C >10 mmol/L (untreated) |
LDL-C cholesterol ≥4.1 mmol/L in children LDL-C cholesterol ≥4.9 mmol/L in adults |
Likely physical symptoms, such as cholesterol deposits in the eye, tendons, knees, elbows and/ or between fingers and toes; these deposits are not always present | May have physical symptoms, such as cholesterol deposits in the eye, tendons, knees, elbows and/or between fingers and toes |
Treatment at time of diagnosis, no matter the age, with a specialist | Treatment as early as age 10 |
Adapted from McGowan and Cuchel et al.
Look for HoFH in your practice
Physical signs and risk factors associated with HoFH:1,3,8
- Untreated LDL-C >10 mmol/L – lower levels should not be discounted if other factors are present
- Cutaneous or tuberous xanthomas – highly suggestive of HoFH in children
- Corneal arcus – highly suggestive of HoFH
- Evidence of CVD – in young children early signs and symptoms are linked to aortic stenosis and regurgitation
- Family history of premature CVD
- Family history of HeFH
References
1. Cuchel M et al. Eur Heart J. 2023;00:1–15; 2. Raal FJ et al. Atherosclerosis. 2018;277:483–492; 3. McGowan MP et al. J Am Heart Assoc. 2019;8:e013225; 4.Tromp TR et al. The Lancet. 2022;399:719-728; 5. Moorjani S et al. Arteriosclerosis. 1989;9:211-6; 6. Seftel HC et al. Br Med J. 1980;281:633-6; 7. Slack J. Atheroscler Rev, 1979;5:35–66; 8. France M et al. Atherosclerosis. 2016;255:128–139;